Neuromuscular junction
Wednesday, September 14, 2022
PARALLEL 1
•
14-PM-Parallel-1
•
4:30 PM
>
6:00 PM
•
Neuromuscular junction
•
Apollon Auditorium
4:30 PM
•
S13L1
•
New treatments for autoimmune myasthenia gravis
>
E.
Emilien
DELMONT (Marseille, France)
5:00 PM
•
S13L2
•
Use of human pluripotent stem cells for Neuromuscular Disorders
>
C.
Cecile
MARTINAT (Evry, France)
5:30 PM
•
S13L3
•
Targeting the neuromuscular junction (NMJ) to treat congenital myasthenic syndromes and inherited motor neuropathies with NMJ dysfunction
>
S.
Sally
SPENDIFF (Ottawa, Canada)
|